Retinoids induce antagonism between FOXO3A and FOXM1 transcription factors in human oral squamous cell carcinoma (OSCC) cells.

TitleRetinoids induce antagonism between FOXO3A and FOXM1 transcription factors in human oral squamous cell carcinoma (OSCC) cells.
Publication TypeJournal Article
Year of Publication2019
AuthorsOsei-Sarfo K, Gudas LJ
JournalPLoS One
Volume14
Issue4
Paginatione0215234
Date Published2019
ISSN1932-6203
KeywordsAntineoplastic Agents, Bexarotene, Carcinoma, Squamous Cell, Cell Line, Tumor, Cell Proliferation, Forkhead Box Protein M1, Forkhead Box Protein O3, Gene Expression, Gene Knockdown Techniques, Histone Deacetylases, Humans, Mouth Neoplasms, Promoter Regions, Genetic, Retinoids, RNA, Messenger, Tretinoin
Abstract

To gain a greater understanding of oral squamous cell carcinoma (OSCC) we investigated the actions of all-trans-retinoic acid (RA; a retinoid), bexarotene (a pan-RXR agonist), and forkhead box (FOX) transcription factors in human OSCC-derived cell lines. RA and bexarotene have been shown to limit several oncogenic pathways in many cell types. FOXO proteins typically are associated with tumor suppressive activities, whereas FOXM1 acts as an oncogene when overexpressed in several cancers. RA and/or bexarotene increased the transcript levels of FOXO1, FOXO3A, and TRAIL receptors; reduced the transcript levels of FOXM1, Aurora kinase B (AURKB), and vascular endothelial growth factor A (VEGFA); and decreased the proliferation of OSCC-derived cell lines. Also, RA and/or bexarotene influenced the recruitment of FOXO3A and FOXM1 to target genes. Additionally, FOXM1 depletion reduced cell proliferation, decreased transcript levels of downstream targets of FOXM1, and increased transcript levels of TRAIL receptors. Overexpression of FOXO3A decreased proliferation and increased binding of histone deacetylases (HDACs) 1 and 2 at the FOXM1, AURKB, and VEGFA promoters. This research suggests novel influences of the drugs RA and bexarotene on the expression of FOXM1 and FOXO3A in transcriptional regulatory pathways of human OSCC.

DOI10.1371/journal.pone.0215234
Alternate JournalPLoS ONE
PubMed ID30978209
PubMed Central IDPMC6461257
Grant ListT32 CA062948 / CA / NCI NIH HHS / United States
R01 DE010389 / DE / NIDCR NIH HHS / United States
R01 DE024394 / DE / NIDCR NIH HHS / United States